OTCM
LBLTF
Market cap0USD
May 13, Last price
0.00USD
Name
Lattice Biologics Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lattice Biologics Ltd. is a biotechnology firm focused on developing, manufacturing, and commercializing biological products designed for bone regeneration. These solutions are utilized globally across dental, spinal, and general orthopedic indications. The company's innovative offerings include novel amniotic fluid-based therapies such as AmnioBoost and AmnioBlast. In addition, their product line features a broad range of allografts, encompassing traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix varieties. These versatile products serve numerous critical medical applications, from enhancing spinal fusion and aiding breast reconstruction post-mastectomy to promoting bone regeneration in foot and ankle surgeries and fostering skull healing after neurosurgery. They also play a role in improving wound repair for burn victims, facilitating hernia repair, addressing subchondral bone defects in knee and other joint surgeries, and supporting various sports medicine procedures, including anterior and posterior cruciate ligament repairs. The company's headquarters are located in Belgrade, Montana.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||